为患有刺激性肠综合征的患者实施数字治疗计划,将其纳入常规护理:对关键利益相关者所感知的障碍和促进者的定性评估
Camilla Thuen1,2, Hanne Karoline Hinderaker3, Elisabeth Kjelsvik Steinsvik4
1Center for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway. camilla.thuen@uib.no.
BMC health services research
|August 10, 2025
概括
刺激性肠综合征 (IBS) 的数字治疗方案改善了获得护理的机会. 实施的主要障碍包括融资和规划,而领导能力和利益相关者的参与是成功融入常规医疗保健的关键促进因素.
科学领域:
- 数字健康数字健康
- 医疗保健管理的管理
- 胃肠病学 胃肠病学
背景情况:
- 数字治疗方案为刺激性肠综合征 (IBS) 管理提供了优势,提高了患者获得多学科干预的机会,并减少了医疗保健系统的压力.
- 尽管有好处,但这些数字计划在日常护理中的实施仍然不足.
- 这项研究系统地确定了影响二级医疗保健中数字IBS治疗计划实施的因素.
研究的目的:
- 系统地识别影响刺激性肠综合征 (IBS) 患者数字治疗计划实施的因素.
- 了解将数字IBS干预措施整合到常规体质二级医疗保健中的障碍和促进因素.
主要方法:
- 定性研究设计利用与16个主要利益相关者进行半结构化访谈.
- 样本包括高级领导,实施领导和转诊医生.
- 综合实施框架 研究指导数据收集和分析.
主要成果:
- 确定了关键障碍:融资 (局外化) 和规划 (实施过程).
- 促进者包括:创新来源/相对优势 (创新),关键事件 (外部设置),变革紧张 (内部设置) 和团队合作 (实施过程).
- 促进特征:领导能力,中层领导/医生机会,以及实施者之间的动机.
结论:
- 对影响日常护理中数字IBS计划实施的多层次因素的新见解.
- 利用促进者和解决障碍对于可持续实施至关重要.
- 研究结果为未来的数字医疗保健计划提供了宝贵的见解,强调早期规划,利益相关者参与和适应性方法.
相关概念视频
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
245
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
245
01:17Irritable Bowel Syndrome I: Introduction
382
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
382
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
302
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
302
01:17Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
420
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
420
01:17Assessment of the Gastrointestinal System I: Subjective Data
280
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
280